SHNI Ventures

SHNI Ventures (operating under the brand ASENBE) is a research-driven dermatology and biotechnology company focused on advancing cellular senescence-based solutions for skin health. The company's proprietary, clinically validated platform, Senostat, is engineered to modulate senescence-associated signaling within the dermal microenvironment to restore the skin's functional balance. ASENBE's flagship offering, the Chromatic Reset Program, is a synchronized clinical regimen consisting of Lumina Surge, Cell Solace, and EpiTurn, designed to treat chronic and resistant pigmentary conditions such as melasma. Operating as a B2B clinical partner, the company collaborates with dermatologists and research institutions to integrate its biologically intelligent, regenerative protocols into clinical practice.